Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 3
A Multi-center, Randomized, Double-masked, Active-comparator-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment…
Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Estimated
~$10 – $8,750
Adverum Biotechnologies, Inc.NCT07482176
Phase 2
Evaluation of the Safety and Tolerability of Ixoberogene Soroparvovec (Ixo-vec) Intravitreal Gene Therapy in the Second (Contralateral) Eye of Participants With Bilateral Neovascular Age-related Macular Degeneration.
The purpose of this study is to evaluate safety, effectiveness and durability of a gene therapy called Ixo-vec (Ixoberogene soroparvovec) when administered to …
Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
Estimated
~$10 – $8,750
Adverum Biotechnologies, Inc.NCT07630649